This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through June 3, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Factors Likely to Decide AB InBev's (BUD) Fate in Q4 Earnings
by Zacks Equity Research
AB InBev (BUD) suffers from a decline in beer sales in the United States, owing to a shift in consumer preference to health drinks. This should impact U.S. beer revenues in the fourth quarter.
Super Bowl Spending, Streaming & Amazon's Big TV Advertising Push
by Benjamin Rains
On this episode of the Full-Court Finance podcast, Associate Stock Strategist Ben Rains dives into the big business behind the Super Bowl as the streaming TV market heats up. Plus, we look at Amazon's huge television advertising push and see who are the biggest Super Bowl spenders.
Here's Why Investing in Monster Beverage (MNST) Makes Sense
by Zacks Equity Research
Monster Beverage (MNST) is poised to benefit from momentum in the energy drinks business and strong international presence. Innovative product launches are also likely to work in its favor.
Tilray Teams Up With Authentic Brands, Stock Down on Sell-Off
by Zacks Equity Research
Tilray (TLRY) signs a marketing agreement with Authentic Brands Group to sell consumer cannabis products.
Tilray Shares Rally as Investor Plans Not to Sell Shares
by Zacks Equity Research
Tilray (TLRY) gains after Privateer Holdings decides not to sell shares in the first half of 2019.
Softness in Beer Hurt Alcohol Stocks, Can Cannabis Change Fate?
by Zacks Equity Research
The alcohol space continues its struggles against soft beer sales and higher costs. Meanwhile, cannabis-infused drinks are gaining popularity.
NFL Recap: Why Climbing TV Ratings Matter & Football's Gambling Future
by Benjamin Rains
On this episode of the Full-Court Finance podcast, Associate Stock Strategist Ben Rains breaks down the newly released 2018 NFL TV ratings. Plus, he dives into the NFL's first-ever sports gambling partnership and what it means for the league's future.
Tilray Gains More Than 200%: Is There More Scope for Growth?
by Zacks Equity Research
Tilray (TLRY) gains more than 200% in the past six months. Strategic deals should propel further growth.
The Zacks Analyst Blog Highlights: GW Pharmaceuticals, Altria, Constellation, Anheuser-Busch and The Stars
by Zacks Equity Research
The Zacks Analyst Blog Highlights: GW Pharmaceuticals, Altria, Constellation, Anheuser-Busch and The Stars
Does AB InBev (BUD) Stock Have Potential to Rebound in 2019?
by Zacks Equity Research
AB InBev (BUD) suffers on account of softness in the beer industry, particularly in the United States, which is hurting its sales. However, its recent venture in cannabis space is encouraging.
Will Monster Beverage's Strategies Cushion the Stock in 2019?
by Zacks Equity Research
Monster Beverage (MNST) witnesses strained margins, owing to higher expenses. However, its solid energy drink category and other efforts are encouraging.
4 Sinfully Good Stocks to Watch in 2019
by Tirthankar Chakraborty
Given the stock market turbulence and specter of slower economic growth this year, investing in sin stocks seems prudent. The products or services in this space are relatively inelastic, and business is recession-proof.
Company News For Dec 21, 2018
by Zacks Equity Research
Companies In The News Are: WBA,BB,CCL,TLRY,BUD
AB InBev (BUD) Enters Booming Cannabis Realm With Tilray Deal
by Zacks Equity Research
AB InBev (BUD) announces partnership with the leading marijuana producer, Tilray.
Boston Beer (SAM) Outpaces Peers: Surges 81.7% in a Year
by Zacks Equity Research
Boston Beer (SAM) moves ahead of peers based on the progress of its three-point growth plan, focused on cost savings, long-term innovation, and revival of Samuel Adams and Angry Orchard brands.
Monster Beverage (MNST) Q3 Earnings & Sales Top Estimates
by Zacks Equity Research
Monster Beverage (MNST) reports solid third-quarter 2018 results. Further, management is on track with the launch of Monster Energy brand which is expected to boost sales.
AB InBev (BUD) Lags on Q3 Earnings & Sales, Retains View
by Zacks Equity Research
AB InBev (BUD) posts earnings and sales miss in third-quarter 2018. Higher commodity prices offset gains from revenue management initiatives, strength in premium brands and cost savings.
Will Soft Beer Sales Hurt AB InBev's (BUD) Earnings in Q3?
by Zacks Equity Research
AB InBev (BUD) suffers due to industry-wide decline in beer sales as consumers shift to healthier drinks. However, the company's robust outlook inspires optimism.
A Deep Dive into the Business of the NBA
by Benjamin Rains
On this episode of the Full-Court Finance podcast, Associate Stock Strategist Ben Rains breaks down the booming, international business of the NBA.
Why The NFL's TV Ratings Are Up & A Unicorn Footwear Startup
by Benjamin Rains
On this episode of the Full-Court Finance podcast, Associate Stock Strategist Ben Rains discusses what's behind the NFL's improving TV ratings and dives into the Silicon Valley footwear startup taking on Nike (NKE) and Lululemon (LULU).
Bear of the Day: Constellation Brands (STZ)
by Benjamin Rains
This alcoholic beverage giant is embarking on a new journey and its earnings revisions are trending in the wrong direction.
Verso, Anheuser-Busch, Alphabet, Amazon and Apple highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Verso, Anheuser-Busch, Alphabet, Amazon and Apple highlighted as Zacks Bull and Bear of the Day
Bear of the Day: Anheuser-Busch InBev (BUD)
by David Bartosiak
There's a storm brewing for AB InBev and the stock is suffering.
New Strong Sell Stocks for October 5th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:
Can Molson Coors Survive on Strategies as Beer Loses Fizz?
by Zacks Equity Research
Molson Coors (TAP) looks attractive, based on its focus on cost savings and premiumization as well as exposure to the marijuana space. But, overall softness in the beer industry weighs on the stock.